Under Consent Decree, J&J Delays Full Return Of Recalled OTCs Until 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson doubled the projected impact on its earnings from the remediation due to the slowdown in sales caused by lower production and additional investments required to remediate and modernize facilities.
You may also be interested in...
Perrigo Takes Two Steps Forward: Generic Allegra Launch, Manufacturing Compliance
Perrigo stokes momentum behind already healthy sales growth with significant steps in separate areas: a green light for regulatory compliance at its main manufacturing plant, and the launch of its generic OTC versions of Sanofi-Aventis' Allegra.
FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
FDA will wield tight oversight of Johnson & Johnson subsidiary McNeil Consumer Healthcare's OTC manufacturing operations under a consent decree filed after the firm's quality-control changes failed to satisfy the agency.
J&J Washes Hands Of Purell As GOJO Eyes Consumer Segment Growth
Johnson & Johnson sells the Purell Hand Sanitizer brand, marking a major consumer health product divestment as the firm seeks to rebound from a troubled year for its consumer business.